Connor Iapoce

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.

Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.

Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.

Panretinal photocoagulation followed by anti-VEGF injections increases the likelihood of PPV, compared with anti-VEGF therapy first.

After an initial switch to faricimab, anatomical measures showed improvement while no functional improvement was identified in real-world data.

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Brolucizumab achieved non-inferiority in mean BCVA change to aflibercept in eyes with nAMD but demonstrated a higher incidence of IOI at 2 years.

A retrospective study in Japan identified 3 cases of non-infectious IOI associated with retinal vasculitis after aflibercept 8 mg treatment.

Heat-related mortality rates in the US notably grew between 1999 and 2023, particularly since 2016.

Moderate to severe anemia was linked to an increase in cardiac arrest or stroke compared with normal hemoglobin levels in critically ill COVID-19 patients.

Nocturnal hypoxia may represent an additional modifiable risk factor for AMD, particularly its neovascular form.

Intensive lipid-lowering treatment regimens were linked to a notable reduction in three-point MACE risk and ACS recurrence versus background statin therapy.

Modifiable risk factors, including elevated HbA1C and blood pressure, were linked to a higher risk of DME development in a large multicenter database.

Combination therapy with ezetimibe led to a greater reduction in LDL-C levels than statin monotherapy, but no significant effect on MACE outcomes.

Across a statewide cohort, more than half of patients were unable to achieve iron deficiency resolution within 3 years.

A systematic review identified a notable link between the first year of statin discontinuation and the risk of adverse cardiovascular outcomes.

Higher olpasiran doses sustained a ~50% placebo-adjusted mean reduction in Lp(a) levels nearly 1 year after the final dose.

A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.

A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.

Higher hemoglobin levels during early postnatal days may protect against the development of ROP in preterm infants.

Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

A ranibizumab biosimilar lowers costs compared with aflibercept across all nAMD subtypes from both the patient and societal perspectives.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.